Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira)-Reference-Cited by-同舟云学术

Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira)

Published:2020-10-26 Issue:1 Volume:12 Page:197-209
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Zenari Luciano,Da Porto Andrea,De Moliner Lorena,Lugli Francesca,Guazzoni Valeria,Groppelli Gloria,Molteni Laura,Bracaccia Massimo,Frison Vera,Simioni Natalino,Bonsembiante Barbara,Miranda Cesare,Lapolla Annunziata

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13300-020-00945-4.pdf

Reference21 articles.

1. Berlie H, Hurren KM, Pinelli NR. Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review. Diabetes Metab Syndr Obes. 2012;5:165–74. https://doi.org/10.2147/DMSO.S27528.

2. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;2018(41):2669–701. https://doi.org/10.2337/dci18-0033.

3. Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15:485–502. https://doi.org/10.1111/dom.12025.

4. Cariou B. Pleiotropic effects of insulin and GLP-1 receptor agonists: potential benefits of the association. Diabetes Metab. 2015;41(6 Suppl 1):6S28–35. https://doi.org/10.1016/S1262-3636(16)30006-4.

5. Castellana M, Cignarelli A, Brescia F, Laviola L, Giorgino F. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2019;35:e3082. https://doi.org/10.1002/dmrr.3082.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI;Diabetes Therapy;2024-09-14

2. Early Conversion of Intensive Insulin Therapy to IDegLira Demonstrates Higher Efficacy and Safety in Reducing Fasting Blood Glucose and HbA1c in T2DM Patients;Diabetes, Metabolic Syndrome and Obesity;2024-08

3. IDegLira for the real‐world treatment of type 2 diabetes in Italy. Final results from the REX observational study;Diabetes, Obesity and Metabolism;2024-02-08

4. Use of IDegLira to Intensify, Simplify, and Increase Appropriateness of Type 2 Diabetes Therapy: A Real-Life Experience;Diabetes Therapy;2023-10-26

5. Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations;Diabetes Therapy;2023-09-22